When was DesignMedix founded?

DesignMedix was founded in 2006 and raised its 1st funding round 1 year after it was founded.

Where is DesignMedix located?

DesignMedix is headquartered in Portland, United States.

Who is the current CEO of DesignMedix?

Lynnor Stevenson of DesignMedix.

Is DesignMedix a funded company?

DesignMedix is a funded company, having raised a total of $4.85M across 13 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Mar 15, 2007.

When was the latest funding round of DesignMedix?

DesignMedix's latest funding was a $***** Series A round on Apr 12, 2017, with participation from 0 investor. Its primary sector is Infectious Diseases. In United States, the Infectious Diseases sector has seen $601M in funding in 2026 to date.

Where does DesignMedix rank among its competitors?

DesignMedix ranks 69th amongst 206 active competitors, of which 76 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was LimmaTech Biologics, which secured $2.2M in Feb, 2024.

Who are the top competitors of DesignMedix?

DesignMedix's top competitors include Spero Therapeutics, Vedanta Biosciences and Locus Biosciences. Among them, LimmaTech Biologics secured the most recent funding round in February, 2024.

DesignMedix - 2026 Company Profile, Team, Funding & Competitors

Company Details

Life science & diagnostic supply: reagents, antibodies, kits, instruments, and services. The company provides a wide array of products and services for research, diagnostics, and life sciences. It offers reagents, antibodies, ELISA kits, PCR kits, proteins, cell culture media, and various assays. The company also supplies diagnostic systems, controls, and reference materials. The offerings extend to include instruments, lab equipment, and related services such as DNA extraction, protein extraction, and cell biology products. The business model supports both research and diagnostic applications, serving diverse needs in the scientific community. The website offers features like sign-in/register, cart, search, and multiple currency options, facilitating a global customer base.

Website: designmedix.com
Email ID: *****@designmedix.com

Key Metrics

Founded Year

2006

Location

Portland, United States

Stage

Series A

Total Funding

$4.85M in 13 rounds

Latest Funding Round

Series A, Apr 12, 2017, $*****

Investors

Oregon Venture Fund & 13 more

Ranked

69^th among 206 active competitors

Similar Companies

Spero Therapeutics & 258 more

View DesignMedix's full profile

DesignMedix has raised a total funding of $4.85M over 13 rounds. Its first funding round was on Mar 15, 2007. DesignMedix has 14 institutional investors.

Here is the list of recent funding rounds of DesignMedix:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 12, 2017	6872538	Series A	4805479	8742209	5274523	5426527
Feb 04, 2016	4936520	Grant (prize money)	3257851	3891965	8390098	HHS
Apr 07, 2015	6391759	Grant (prize money)	3000707	1762158	5647513	Business Oregon

Access funding benchmarks and valuations. Sign up today!

View details of DesignMedix's funding rounds and investors

The founders of DesignMedix is Lynnor Stevenson.

Here are the details of DesignMedix's key team members:

Lynnor Stevenson: Co-Founder & CEO of DesignMedix and founder of 1 other company.

View details of DesignMedix's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of DesignMedix include Spero Therapeutics, Vedanta Biosciences and Locus Biosciences. Here is the list of Top 10 competitors of DesignMedix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Spero Therapeutics 2013, Cambridge (United States), Public	Developer of therapeutics for drug-resistant bacterial infections	$115M	Atlas Venture, Partners Health Care Innovation ... & 16 others	71/100
2nd	Vedanta Biosciences 2010, Cambridge (United States), Series E	Developer of therapeutics to treat infectious diseases	$350M	Invesco, Seventure Partners & 38 others	65/100
3rd	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Artis Ventures, Illumina & 13 others	64/100
4th	LimmaTech Biologics 2015, Schlieren (Switzerland), Acquired	Developing bioconjugate vaccines using glycoengineering and protein glycosylation techniques	$40M	REPAIR Impact Fund, Adjuvant Capital & 4 others	63/100
5th	Melinta Therapeutics 2000, Morristown (United States), Acquired	Developer of therapeutics for antibiotic-resistant infections	$186M	Warburg Pincus, SR One & 16 others	61/100
6th	Paratek Pharma 1996, Boston (United States), Acquired	Developer of therapeutics for antimicrobial resistant infections	$96.5M	HBM Healthcare Investments, Phase4 Partners ... & 25 others	61/100
7th	Everest Medicines 2017, New York City (United States), Public	Developer of drugs for the treatment of cancer	$313M	HBM Healthcare Investments, RA Capital Management ... & 12 others	61/100
8th	Bioversys 2008, Basel (Switzerland), Public	Developer of therapeutics for Antimicrobial Resistance	$62.5M	AMR Action Fund, Wellcome Trust & 10 others	61/100
9th	MicuRx Pharmaceuticals 2007, Foster City (United States), Series E	Develops antibiotics against multidrug-resistant (MDR) superbug infections	$272M	Legend Capital, BioVeda China Fund & 9 others	60/100
10th	UTILITY therapeutics 2017, Altrincham (United Kingdom), Acquired	Developer of antibiotics to treat urinary tract infections and multi-drug resistant infections	$2.52M	Dacco Invest, Adam Invest & 8 others	58/100
69th	DesignMedix 2006, Portland (United States), Series A	Life science & diagnostic supply: reagents, antibodies, kits, instruments, and services	$4.85M	Golden Seeds, Oregon Venture Fund & 12 others	39/100